Company: OSRH
Filing Date: 2025-08-19
Form Type: PRE 14A
Source: 0001213900-25-078140
Chunk: 18

Company: OSR Holdings, Inc.
Filing Date: 2025-08-19
Form: PRE 14A
Chunk 18
---
 and its subsidiaries’
growth and expansion as a cross-border healthcare investment group in three countries: the U.S., South Korea and Switzerland. He is also
the Chief Executive Officer of BCME, a position he has held since March 2020, and the Chairman of the Board of Vaximm AG since November
2022. Since July 2019 until April 2021 and December 2022 to August 2024, Mr. Hwang has also served as Chief Executive Officer of OSR,
a global drug development company and a subsidiary of BCM, where he has also served as chairman since July 2019. Prior to founding BCM
in 2012, Mr. Hwang served with financial services firms in Korea and the U.S., including North Head Capital Partners LLC from 2011-2012,
Kim Eng Research Korea and Kim Eng Securities USA from 2006-2008, and Shinhan Investment Corp from 2002-2004 and 2006. Mr. Hwang received
a BA in sociology from Korea University in 1998. Mr. Hwang is well qualified as Chief Executive Officer and President of the Company because
of his significant investment and capital markets expertise within the healthcare industry.

<div align='center'>9</div>

Jun Chul Whang is Chief Legal Officer and Secretary of
the Company as of February 14, 2025. Mr. Whang has been a director of the Company since August 2020. Mr. Whang has been an advisor
to BCM since January 2015, and starting in June 2018, has served as General Counsel and consultant to BCM. In August 2020, he became a
member of BCM. As a member, Mr. Whang provides legal and strategic advice to BCM on cross-border transactional matters. Since December
2020, Mr. Whang has also served as General Counsel of Minetta Brook Capital LLC, a boutique financial advisory firm that also serves as
general partner to investment vehicles. From April 2019 through July 2023, Mr. Whang also served as General Counsel to ELA Partners
(an affiliate of Stonehaven, a global capital raising fintech platform), which specializes in capital raising for selective alternative
investment opportunities globally. From May 2016 to May 2018, Mr. Whang was Partner at the law firm of Greenspoon Marder (“GM”).
Mr. Whang was also Partner (having joined as an associate) at the law